1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022

Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022

Summary

Schizophrenia is a persistent long-term brain disorder that causes severe, debilitating psychotic episodes. Its core symptoms, auditory or visual hallucinations, are often accompanied by fixed, false, and often paranoid beliefs, called delusions. These two features are often combined with learning and cognitive deficits. WHO experts have estimated that roughly 24 million people are affected by schizophrenia worldwide. While the arrival of atypical antipsychotics has greatly expanded pharmacologic treatment options over the past two decades, the current drug market does not treat the negative and cognitive symptoms that are associated with the disease. GlobalData expects that the growing popularity of long-acting injectable (LAI) antipsychotics, along with the arrival of novel treatments that achieve higher efficacy in negative- and cognitive-predominant patients, will serve to stimulate growth in the marketplace over the forecast period. Country-specific treatment recommendations and policy implementation will be an essential metric for determining future mental health services in the 7MM.

Olanzapine (Zyprexa; Eli Lilly) is a second-generation antipsychotic that also acts as an antagonist at D2/D3 receptors. But unlike most agents in its class, Zyprexa has a higher relative affinity for serotonin 5-HT2A receptors in comparison to D2/D3 dopaminergic binding sites, a feature that it shares only with clozapine and quetiapine. However, Zyprexa’s activity on M1 and M3 muscarinic and H1 histaminergic receptor sites imply an association with metabolic dysregulation and Zyprexa’s industry reputation has led to tolerability and safety concerns.

Scope

- Overview of Schizophrenia, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on Zyprexa including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Zyprexa for the top seven countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Schizophrenia
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of Zyprexa performance
- Obtain sales forecast for Zyprexa from 2012-2022 in the top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Table Of Contents

Zyprexa (Schizophrenia) - Forecast and Market Analysis to 2022
1 Table of Contents

2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Reports 10
3 Disease Overview 11
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 12
3.2 Symptoms 13
4 Disease Management 15
4.1 Diagnosis 15
4.1.1 Subjective Assessments 16
4.1.2 Disease Subtypes 17
4.2 Treatment Overview 20
4.2.1 Treatment of Acute Agitation Associated with Schizophrenia 22
4.2.2 Maintenance Treatment of Schizophrenia 23
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26
6 Zyprexa (olanzapine) 28
6.1 Overview 28
6.2 Efficacy in Acute Treatment 30
6.3 Efficacy in Maintenance Treatment 30
6.4 Safety 31
6.5 SWOT Analysis 32
6.6 Forecast 32
7 Appendix 33
7.1 Bibliography 33
7.2 Abbreviations 36
7.3 Methodology 37
7.4 Forecasting Methodology 37
7.4.1 Diagnosis and Treatment Rates 37
7.4.2 Adherence Rates 38
7.4.3 General Pricing Assumptions 38
7.4.4 Drug Assumptions 40
7.4.5 Generic Erosion 40
7.5 Key Opinion Leaders 41
7.6 About the Authors 42
7.6.1 Author 42
7.6.2 Reviewers 42
7.6.3 Global Head of Healthcare 43
7.7 About GlobalData 44
7.8 Disclaimer 44

1.1 List of Tables

Table 1: Symptom Clusters of Schizophrenia 14
Table 2: Common Subjective Rating Scales Employed in Schizophrenia Diagnosis 17
Table 3: Development-Based Classification of Antipsychotic Drugs 20
Table 4: Receptor Binding Profiles of Atypical Antipsychotics 21
Table 5: Guidelines for the Treatment of Schizophrenia 22
Table 6: Leading Branded Treatments for Schizophrenia, 2013 27
Table 7: Strategic Competitor Assessment of the Marketed Products in Schizophrenia, 2014 27
Table 8: Product Profile - Zyprexa 29
Table 9: Zyprexa SWOT Analysis, 2014 32
Table 10: Global Sales Forecast ($m) for Zyprexa, 2012-2022 32

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025

  • $ 10995
  • Industry report
  • November 2016
  • by GlobalData

PharmaPoint: Schizophrenia - Global Drug Forecast and Market Analysis to 2025 Summary Schizophrenia is a heterogeneous behavioral and cognitive syndrome involving chronic or recurrent psychosis. The disorde ...

Global and Chinese Paliperidone Palmitate (CAS 199739-10-1) Industry, 2017 Market Research Report

Global and Chinese Paliperidone Palmitate (CAS 199739-10-1) Industry, 2017 Market Research Report

  • $ 3000
  • Industry report
  • February 2017
  • by Prof Research

The 'Global and Chinese Paliperidone Palmitate Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Paliperidone Palmitate industry with a ...

Global and Chinese Levosulpiride (CAS 23672-07-3) Industry, 2017 Market Research Report

Global and Chinese Levosulpiride (CAS 23672-07-3) Industry, 2017 Market Research Report

  • $ 3000
  • Industry report
  • February 2017
  • by Prof Research

The 'Global and Chinese Levosulpiride Industry, 2012-2022 Market Research Report' is a professional and in-depth study on the current state of the global Levosulpiride industry with a focus on the Chinese ...


Download Unlimited Documents from Trusted Public Sources

Therapy Market in the UK

  • February 2017
    12 pages
  • Therapy  

  • United Kingdom  

View report >

Therapy Market in the US

  • February 2017
    254 pages
  • Therapy  

    Anti-Infective  

    Hormone  

  • United States  

View report >

Hospital Industry in Asia

  • February 2017
    16 pages
  • Hospital  

    Therapy  

  • Asia  

View report >

Related Market Segments :

Antipsychotic
Therapy
Psychotic Disorder

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.